Muscarinic agonist-mediated increases in serum corticosterone levels are abolished in m(2) muscarinic acetylcholine receptor knockout mice.
- Authors
- Hemrick-Luecke, S K; Bymaster, F P; Evans, D C; Wess, J; Felder, C C
- Year
- 2002
- Journal
- The Journal of pharmacology and experimental therapeutics
- PMID
- 12235238
- DOI
- 10.1124/jpet.102.036020
Muscarinic acetylcholine receptors (M(1)-M(5)) regulate many key functions in the central and peripheral nervous system. Due to the lack of receptor subtype-selective ligands, however, the physiological roles of individual muscarinic receptor subtypes remain to be determined. In this study, we examined the effects of the muscarinic M(2)/M(4) receptor-preferring agonist [5R-(exo)]-6-[4-butylthio-1,2,5-thiadiazol-3-yl]-1-azabicyclo-[3.2.1]-octane (BuTAC) on serum corticosterone levels in M(2) and M(4) receptor single knockout (KO) and M(2,4) receptor double KO mice. Responses were compared with those obtained with the corresponding wild-type (WT) mice. BuTAC (0.03-0.3 mg/kg s.c.) dose dependently and significantly increased serum corticosterone concentrations in WT mice to 5-fold or greater levels compared with vehicle controls. In muscarinic M(2) and M(2,4) KO mice, however, BuTAC had no significant effect on corticosterone concentrations at doses of 0.1, 0.3, and 1 mg/kg s.c. In both WT and muscarinic M(4) KO mice increases in serum corticosterone concentrations induced by BuTAC (0.1 and 0.3 mg/kg) were not significantly different and were blocked by scopolamine. In summary, the muscarinic M(2,4)-preferring agonist BuTAC had no effect on corticosterone levels in mice lacking functional muscarinic M(2) receptors. These data suggest that the muscarinic M(2) receptor subtype mediates muscarinic agonist-induced activation of the hypothalamic-pituitary-adrenocortical axis in mice.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Co-occurring risk factors for alcohol dependence and habitual smoking: update on findings from the Collaborative Study on the Genetics of Alcoholism. | 2006 | 17373405 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Mirabegron and solifenacin are effective for the management of the increased urinary frequency induced by psychological stress in female mice. | West EG et al. | β | 2022 | β |
| Modulation of Muscarinic Signalling in the Central Nervous System by Steroid Hormones and Neurosteroids. | Szczurowska E et al. | β | 2022 | β |
| Melanopsin (Opn4) utilizes GΞ±<sub>i</sub> and GΞ²Ξ³ as major signal transducers. | Kankanamge D et al. | β | 2018 | β |
| M<sub>3</sub>-subtype muscarinic receptor activation stimulates intracellular calcium oscillations and aldosterone production in human adrenocortical HAC15 cells. | Malaiyandi LM et al. | β | 2018 | β |
| Physiological roles of CNS muscarinic receptors gained from knockout mice. | Thomsen M et al. | β | 2018 | β |
| The role of glutamatergic, GABA-ergic, and cholinergic receptors in depression and antidepressant-like effect. | Pytka K et al. | β | 2016 | β |
| Muscarinic pain pharmacology: realizing the promise of novel analgesics by overcoming old challenges. | Fiorino DF et al. | β | 2012 | β |
| Overview of muscarinic receptor subtypes. | Eglen RM | β | 2012 | β |
| Sleep, activity, temperature and arousal responses of mice deficient for muscarinic receptor M2 or M4. | Turner J et al. | β | 2010 | β |
| Depression Case Control (DeCC) Study fails to support involvement of the muscarinic acetylcholine receptor M2 (CHRM2) gene in recurrent major depressive disorder. | Cohen-Woods S et al. | β | 2009 | β |
| Evaluation of [18F]fluoroxanomeline {5-{4-[(6-[18F]fluorohexyl)oxy]-1,2,5-thiadiazol-3-yl}-1-methyl-1,2,3,6-tetrahydropyridine} in muscarinic knockout mice. | Kiesewetter DO et al. | β | 2007 | β |
| Co-occurring risk factors for alcohol dependence and habitual smoking: update on findings from the Collaborative Study on the Genetics of Alcoholism. | Grucza RA et al. | β | 2006 | β |
| Muscarinic receptor subtype pharmacology and physiology. | Eglen RM | β | 2005 | β |
| Pituitary-adrenal responses to cholinergic stimulation and acute mild stress are differentially elevated in male and female M(2) muscarinic receptor knockout mice. | Rhodes ME et al. | β | 2005 | β |
| Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. | Wess J | β | 2004 | β |
| Alteration in behavioral sensitivity to amphetamine after treatment with oxotremorine. Effect of dose and test environment. | Gralewicz S et al. | β | 2003 | β |
| Novel insights into muscarinic acetylcholine receptor function using gene targeting technology. | Wess J | β | 2003 | β |
| The neurobiology and control of anxious states. | Millan MJ | β | 2003 | β |
| Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. | Bymaster FP et al. | β | 2003 | β |